Ranjbar Fatemeh, Akbarzadeh Fariborz, Asadlou Mahboub
Clinical Psychiatry Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Iran J Psychiatry. 2016 Oct;11(4):234-238.
The aim of this study was to evaluate the effect of Premenstrual Syndrome (PMS) treatment with selective serotonin reuptake inhibitor (SSRI) on treatment response of refractory hypertension of the patients. This was a triple-blind randomized clinical trial conducted on female patients suffering from refractory hypertension and PMS at the same time. We obtained informed consent from 40 patients who had inclusion criteria and selected 20 patients for the intervention (sertraline 50 mg daily) and 20 for the control groups. The study period was five weeks. The mean of systolic and diastolic blood pressure before and after intervention was measured separately for each individual in each group and the mean of blood pressure of the members of the two groups were compared with each other. The mean age of the participants was 43.60 ± 4.57. In this study, systolic and diastolic blood pressure of both groups reduced after intervention. The mean of systolic blood pressure was reduced by 40.86 mmHg in the intervention group and this reduction was 16 mm Hg in control group after intervention (P<0.001). Comparing this reduction between the two groups, we found that reduction rate in systolic blood pressure of the two groups did not have a significant statistical difference before and after the intervention (P = 0.11). Mean of diastolic blood pressure also showed reduction of 9.17 mm Hg and that of control group showed 6.7-mmHg reduction. Reduction rate of diastolic blood pressure in the intervention group had a statistically significant difference with that of the control group (P<0.017). : Administration of sertraline is more effective in controlling diastolic blood pressure in women suffering from refractory hypertension and comorbid PMS.
本研究的目的是评估选择性5-羟色胺再摄取抑制剂（SSRI）治疗经前期综合征（PMS）对难治性高血压患者治疗反应的影响。这是一项针对同时患有难治性高血压和PMS的女性患者进行的三盲随机临床试验。我们从40名符合纳入标准的患者中获得了知情同意书，并选择20名患者进行干预（每日服用50毫克舍曲林），另外20名作为对照组。研究期为五周。分别测量每组中每个个体干预前后的收缩压和舒张压平均值，并比较两组成员的血压平均值。参与者的平均年龄为43.60±4.57。在本研究中，两组的收缩压和舒张压在干预后均有所降低。干预组的收缩压平均值降低了40.86毫米汞柱，对照组在干预后的降低值为16毫米汞柱（P<0.001）。比较两组之间的这种降低情况，我们发现两组收缩压的降低率在干预前后没有显著的统计学差异（P = 0.11）。舒张压平均值也显示降低了9.17毫米汞柱，对照组降低了6.7毫米汞柱。干预组舒张压的降低率与对照组有统计学显著差异（P<0.017）。：对于患有难治性高血压和合并PMS的女性，服用舍曲林在控制舒张压方面更有效。
